{{Rsnum
|rsid=7940423
|Gene=GALNTL4
|Chromosome=11
|position=11482681
|Orientation=plus
|GMAF=0.03581
|Gene_s=GALNTL4
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 0.0 | 0.9 | 99.1
| HCB | 0.0 | 0.0 | 100.0
| JPT | 0.0 | 0.0 | 100.0
| YRI | 2.7 | 23.8 | 73.5
| ASW | 0.0 | 14.0 | 86.0
| CHB | 0.0 | 0.0 | 100.0
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 1.0 | 99.0
| LWK | 2.7 | 30.9 | 66.4
| MEX | 0.0 | 1.7 | 98.3
| MKK | 0.0 | 16.0 | 84.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}{{PMID Auto GWAS
|PMID=22491018
|Trait=None
|Title=Genome-wide association analysis implicates the involvement of eight loci with response to tocilizumab for the treatment of rheumatoid arthritis.
|RiskAllele=
|Pval=1E-7
|OR=10.9000
|ORtxt=None
}}

{{on chip | Affy GenomeWide 6}}
{{on chip | HumanOmni1Quad}}